{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-013441","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.401179+00:00","generated_at":"2026-06-03T06:39:38.586864+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Clene enters amended supply/license deal with 4Life; waives $960K default","bullets":["Amended exclusive supply agreement: price cost +20%; 4Life commits to minimum sales of $5M in 2024, $10M 2025, $20M 2026, $30M 2027–2028.","Amended exclusive license agreement grants 4Life royalty-bearing license (3% of incremental sales) through 2033; renewable for 5-year terms.","Clene waived $960K payment default by 4Life to maintain the long-term relationship.","After Jan 1, 2027, Clene may sell licensed products via third-party retail or its own websites."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-013441","json":"https://secwatch.observer/filing/0001437749-24-013441.json","markdown":"https://secwatch.observer/filing/0001437749-24-013441.md","text":"https://secwatch.observer/filing/0001437749-24-013441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924013441/0001437749-24-013441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924013441/clnn20240417_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:39:38.586864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"695f3b3b691fead4f9f0df8b89f61c90129e2ad8","claim":"Clene Inc. entered into Amended and Restated Exclusive Supply Agreement with 4Life Research, LLC valued at cost plus 20% purchase price; Minimum Sales Commitments through 2033; royalty rate 3% of incremental (effective 2024-04-25).","evidence_excerpt":"On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924013441/0001437749-24-013441-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"4Life Research, LLC"},{"label":"Value","value":"cost plus 20% purchase price; Minimum Sales Commitments through 2033; royalty rate 3% of incremental"},{"label":"Effective","value":"2024-04-25"}]},{"claim_id":"aa543461a8af6d19b843d04f8f7dd1e0173164ac","claim":"Clene Inc. entered into Amended and Restated License Agreement with 4Life Research, LLC valued at exclusive, royalty bearing license; royalty rate 3% of incremental sales; term through 2033 (effective 2024-04-25).","evidence_excerpt":"On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924013441/0001437749-24-013441-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"4Life Research, LLC"},{"label":"Value","value":"exclusive, royalty bearing license; royalty rate 3% of incremental sales; term through 2033"},{"label":"Effective","value":"2024-04-25"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}